Saturday 17 October 2026 Export ABVC’s income statement to Excel — free account

ABVC BioPharma, Inc.

ABVC BioPharma, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $509,600.00, up 234.4% from fiscal 2023. In the quarter to June 2026, revenue grew 66,233.3%, EPS grew 76.9% and free cash flow grew 72.7%, each against the same quarter a year earlier.

0.92 0.01 −1.08%

Follow ABVC

Alert me

Market cap: $24.9M
P/E: 0.0×
Fwd P/E: −1.6×
Dividend yield: —
F-score: 6/9
Altman Z: −14.88
Beneish M: −3.98
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 16.11%

Capital & Financial Ratios $m

Market Cap 24.89

Revenue 1.30

Net Income (7.60)

Free Cash Flow (2.69)

Net Debt (0.09)

Current Ratio 0.07

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.59)

P/S ratio 18.38

P/B ratio 1.95

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth 718.29%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 12.76%

10-year low 10-year high

P/B against its own 10 years 19.67%

10-year low 10-year high

EV/Sales against its own 10 years 11.51%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1	1	1	0
Receivables	1	1	—	—
Inventory	—	—	—	—
Other	1	1	1	0
	2	2	3	0

	2023	2024	2025	Q'26
Payables	—	—	—	—
ST’ Debt	—	—	—	—
Other	0	0	0	0
	6	7	6	6

Compound Annual Growth %

	10y	5y	3y
Sales	—	(6.20%)	12.72%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	37.95%	60.17%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	1	—	—
’24	0	0	0	0	1
’23	0	0	0	0	0
’22	0	0	0	1	1
’21	0	0	0	0	0
’20	0	0	0	0	0
’19	0	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	0	—	—	—
’25	(1)	(1)	(1)	(1)	(3)
’24	(1)	0	0	(1)	(2)
’23	(1)	(1)	(1)	0	(4)
’22	(3)	(3)	(1)	0	(7)
’21	(1)	(1)	(2)	(3)	(8)
’20	(1)	(1)	0	(2)	(5)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	0	—	—	—
’25	(1)	(1)	(1)	(1)	(3)
’24	(1)	0	0	(1)	(2)
’23	(1)	(1)	(1)	0	(4)
’22	(3)	(3)	(1)	0	(8)
’21	(1)	(1)	(2)	(3)	(8)
’20	(1)	(1)	0	(2)	(5)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.06)	(0.03)	—	—	—
’25	(0.06)	(0.13)	(0.09)	(0.16)	(0.39)
’24	(0.30)	(0.09)	(0.04)	0.04	(0.42)
’23	(0.60)	(0.68)	(0.82)	(0.35)	(1.91)
’22	(2.00)	(0.60)	(1.10)	(1.50)	(5.20)
’21	(0.49)	(0.80)	(0.70)	(3.10)	(5.10)
’20	(0.60)	(0.90)	(0.90)	(2.49)	(5.37)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	180.00	360.00	270.00	12.50	10.50	19.50	5.00	0.67	0.41	0.40	Analyst estimates 2026–2028 Powerpack
	High	1,433.12	360.00	360.00	378.00	55.00	116.90	39.40	18.70	2.45	5.48
People
People	Employees	9	9	38	5	34	30	23	19	19	19
	Revenue/emp, $m	0.00	0.00	0.00	0.14	0.01	0.01	0.04	0.01	0.03	0.00
Income, $m
Income, $m	Revenue	—	—	0	1	0	0	1	0	1	—
	Gross margin, %	0.00	—	(2,547.14)	97.14	96.13	98.57	70.47	(98.16)	99.84	—
	EBT	(11)	(4)	(6)	(4)	(11)	(11)	(16)	(8)	(5)	(8)
	EBT margin, %	0.00	0.00	(91,851.43)	(571.51)	(2,238.90)	(3,150.87)	(1,599.77)	(5,265.62)	(1,053.69)	0.00
	Net income	(11)	(4)	(6)	(4)	(11)	(12)	(16)	(8)	(5)	(8)
	Depreciation	—	—	0	0	0	0	0	0	0	1
Per share, $
Per share, $	Revenue	0.00	0.00	0.01	0.40	0.25	0.14	0.31	0.04	0.04	0.00
	Earnings	(1.08)	(3.58)	(5.22)	(2.10)	(4.63)	(5.10)	(5.20)	(1.91)	(0.42)	(0.39)
	Cash flow	(0.32)	(1.25)	(0.78)	(1.79)	(2.31)	(3.03)	(2.34)	(0.97)	(0.15)	(0.15)
	Capex	0.00	0.00	0.00	0.00	0.00	(0.01)	(0.04)	0.00	0.00	0.00
	Free cash flow	(0.32)	(1.25)	(0.78)	(1.79)	(2.31)	(3.04)	(2.37)	(0.97)	(0.15)	(0.15)
	Book value	(0.59)	(1.48)	(4.60)	(0.07)	1.35	3.54	1.02	0.29	0.06	0.66
	Shares, m	11	1	1	2	2	3	3	4	12	20
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
	P/S	—	—	63,310.91	108.98	208.14	238.71	19.59	34.12	13.52	—
	P/B	—	—	0.00	0.00	37.77	9.58	5.87	4.15	9.51	—
	EV/Sales	—	—	63,320.35	109.75	208.79	226.39	21.88	51.06	15.10	—
	EV/FCF	—	—	(464.09)	(24.57)	(22.10)	(10.58)	(2.82)	(1.85)	(4.19)	—
Cash, $m
Cash, $m	Operating cash flow	(3)	(1)	(1)	(3)	(5)	(8)	(7)	(4)	(2)	(3)
	Capex	—	—	—	—	—	0	0	0	—	—
	Free cash flow	(3)	(1)	(1)	(3)	(5)	(8)	(8)	(4)	(2)	(3)
Balance, $m
Balance, $m	Working capital	(6)	(2)	(10)	(6)	1	4	(3)	(4)	(4)	(4)
	Total debt	—	1	0	0	3	4	4	—	—	—
	Net debt	0	1	0	0	(2)	(7)	(1)	(1)	(1)	(1)
	Shareholders’ equity	(6)	(2)	(5)	0	3	9	3	1	1	13
Returns, %
Returns, %	ROA	(6,205.02)	(157.20)	(129.91)	(56.60)	(105.65)	(101.47)	(141.11)	(89.70)	(63.99)	(55.30)
	ROIC	0.00	0.00	0.00	0.00	(1,864.65)	(333.03)	(534.12)	(924.61)	0.00	(37.54)
	ROE	172.56	269.39	157.11	133.27	(771.78)	(222.66)	(271.31)	(346.94)	(495.87)	(112.81)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Sep 2025 · fundamentals updated 28 Sep 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ATOS Atossa Therapeutics, Inc.	$26.4M	— (loss-making)	—	−94.28% (below 0%: shrinking)	n/m	−32.86% (below 0%: shrinking)	0.00%	0.00%	Compare
IGC IGC Pharma, Inc.	$26.3M	— (loss-making)	— (loss-making)	−19.70% (below 0%: shrinking)	n/m	−103.33% (below 0%: shrinking)	18.11%	(1,050.57%)	Compare
MCRB Seres Therapeutics, Inc.	$25.2M	— (loss-making)	— (loss-making)	+96.79% (above 0%: growing)	n/m	−66.15% (below 0%: shrinking)	100.00%	(2,890.35%)	Compare
ABVC ABVC BioPharma, Inc.	$24.9M	— (loss-making)	— (loss-making)	+66,233.33% (above 0%: growing)	n/m	+72.66% (above 0%: growing)	100.00%	0.00%
BYSI BeyondSpring Inc.	$23.9M	— (loss-making)	— (loss-making)	+87.78% (above 0%: growing)	n/m	+35.78% (above 0%: growing)	100.00%	0.00%	Compare
CYAD Celyad SA	$23.8M	— (loss-making)	— (loss-making)	—	n/m	+78.72% (above 0%: growing)	0.00%	0.00%	Compare
PLRZ Polyrizon Ltd.	$23.7M	—	—	—	—	−744.51% (below 0%: shrinking)	—	—	Compare
IMMP Prima BioMed Ltd	$23.7M	— (loss-making)	—	—	n/m	−589,653.13% (below 0%: shrinking)	100.00%	(101.89%)	Compare
EVAX Evaxion A/S - Sponsored ADR	$23.4M	— (loss-making)	— (loss-making)	+14,590.20% (above 0%: growing)	n/m	−56.70% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$23.9M	—	—	+87.78%	—	−61.42%	100.00%	0.00%

All 614 Biotechnology stocks →

ABVC BioPharma, Inc. (ABVC) key facts

Strength: ABVC BioPharma, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $509,600.00, up 234.4% from fiscal 2023.
ABVC BioPharma, Inc. (ABVC) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ABVC traded at $0.92, a market capitalization of $24.9 million.
Return on equity was −112.8% and debt-to-equity 0.00.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is −14.88 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Sep 28, 2026.